Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of ASC09/Ritonavir for COVID-19 Pneumonia
NCT04261270Phase 3Unknown
- Sponsor
- Tongji Hospital
- Start
- Feb 2020
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of TMC-310911 in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Tongji Hospital. Primary endpoint: Rate of comprehensive adverse outcome at 14 days. Status: unknown.
02
Drugs
TMC-310911
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04261270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04261270.